Drug Profile
Etaracizumab
Alternative Names: Abegrin; Anti-alpha-v-beta-3 humanised monoclonal antibody; Anti-αvβ3 monoclonal antibody; LM 609; MEDI-522; Vitaxin; Vitaxin IILatest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator Applied Molecular Evolution; MedImmune
- Developer Targesome
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunostimulants; Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Malignant melanoma; Prostate cancer; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 09 Mar 2007 Discontinued - Phase-II for Malignant melanoma in USA (IV-infusion)
- 09 Mar 2007 Discontinued - Phase-II for Prostate cancer in USA (IV-infusion)